Search clinical trials for: Ciclesonide Placebo

Total 53604 results

West Penn Allegheny Health System

Completed

Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis

Asthma | Allergic Rhinitis

United States
University of Chicago
Sunovion

Withdrawn

A Pilot Investigation of Ciclesonide When Administered as a Hypotonic Versus an Isotonic Formulation of Ciclesonide Nasal Spray

Allergic Rhinitis

United States
Sunovion

Completed

Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older

Seasonal Allergic Rhinitis

United States
Sunovion

Completed

Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis

Seasonal Allergic Rhinitis

United States
Sunovion

Completed

A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older

Allergic Rhinitis | Perennial Allergic Rhinitis

United States
Sunovion

Completed

A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR)

Seasonal Allergic Rhinitis

United States
Sunovion

Completed

A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).

Perennial Allergic Rhinitis | PAR

United States
Hamilton Health Sciences Corporation
Takeda; Kolding Sygehus

Completed

Effect of Ciclesonide on Exercise Induced Bronchoconstriction

Asthma

Canada
AstraZeneca

Completed

Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602)

Rhinitis, Allergic, Seasonal

United States
AstraZeneca

Completed

To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010/M1-405)

Rhinitis, Allergic, Perennial | Hay Fever

United States
AstraZeneca

Completed

Efficacy and Safety of Ciclesonide Nasal Spray in Participants With Seasonal Allergic Rhinitis (SAR) in Russia

Seasonal Allergic Rhinitis

Russian Federation
Sunovion

Completed

Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis

Perennial Allergic Rhinitis | PAR

United States
Sunovion

Completed

A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR)

Perennial Allergic Rhinitis

United States
McGill University Health Centre/Research Institute...

Terminated

Inhaled Ciclesonide for Outpatients With COVID19 (CONTAIN)

COVID 19

Canada
Allergy & Asthma Medical Group & Research Center

Completed

Evaluation of Traditional Paper Symptom Diary vs. the VOCEL Mobile Diary

Asthma

United States
Sanofi
Takeda

Completed

Effects of Ciclesonide MDI 50mg/Day and 200mg/Day (Ex-Valve) Once-Daily on Growth in Children With Mild Persistent Asthma

Asthma
Sanofi

Completed

Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid

Asthma

United States
Sanofi

Completed

Efficacy of Ciclesonide vs Placebo Administered as Once Daily or Twice Daily in Patients Not Treated With Inhaled Corticosteroid.

Asthma

United States, Brazil, Poland, Russian Federation, Estonia, Mexico, Israel, Chile, Latvia, Puerto Rico, Costa Rica
AstraZeneca

Completed

Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)

Seasonal Allergic Rhinitis | Hay Fever

United States
Ola Blennow, MD, PhD
Karolinska University Hospital; Danderyd Hospital; Centrallasarettet Västerås

Active, not recruiting

Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19) (HALT)

Pneumonia, Viral | Covid-19 | Sars-CoV2

Sweden
Sunovion

Completed

Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis

Perennial Allergic Rhinitis

United States
Sunovion

Completed

Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray

Perennial Allergic Rhinitis

United States
AstraZeneca

Completed

A Study of Ciclesonide Nasal Spray in Patients 18 Years and Older With Seasonal Allergic Rhinitis (BY9010/M1-413)

Rhinitis, Allergic, Seasonal | Hay Fever

Canada
Sunovion

Completed

A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older

Perennial Allergic Rhinitis

United States
Covis Pharma S.à.r.l.

Completed

A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients

COVID-19

United States
AstraZeneca

Completed

Ciclesonide for the Treatment of Airway Hyperresponsiveness

Asthma

Switzerland
Korea University Guro Hospital

Completed

A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19

COVID-19

Korea, Republic of
Sanofi
Takeda

Completed

Effects Of Ciclesonide And Beclomethasone On Lens Opacification In Adult Subjects With Moderate To Severe Persistent Asthma

Respiratory Tract Diseases | Asthma | Respiratory Hypersensitivity

France
AstraZeneca

Completed

Efficacy and Safety of Ciclesonide in Preschool Children With Asthma (2 to 6 Years) (BY9010/M1-207)

Asthma

Hungary, South Africa, Germany, Brazil, India, Spain, Netherlands, Poland, Switzerland
AstraZeneca

Completed

Study Using the Environmental Exposure Unit (EEU) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-407)

Rhinitis, Allergic, Seasonal | Hay Fever

Canada
Apotex Inc.

Completed

A Study Comparing The Bioequivalence Of Ciclesonide Nasal Spray (Apotex, Inc.) To That Of Omnaris™ Nasal Spray (Sepracor, Inc.) In The Treatment Of Seasonal Allergic Rhinitis

Seasonal Allergic Rhinitis
AstraZeneca

Completed

Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.

Asthma

Russian Federation, Hungary, South Africa, Mexico, United States, Poland
AstraZeneca

Completed

Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in Treatment of Seasonal Allergic Rhinitis (BY9010/M1-406)

Rhinitis, Allergic, Seasonal | Hay Fever

Canada
AstraZeneca

Completed

To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-401)

Rhinitis, Allergic, Seasonal | Hay Fever

United States
AstraZeneca

Completed

To Assess the Safety and Efficacy of Ciclesonide Applied as a Nasal Spray in the Treatment of Perennial Allergic Rhinitis (BY9010/M1-402)

Rhinitis, Allergic, Perennial

United States
AstraZeneca

Completed

Efficacy of Ciclesonide Inhaled Once Daily Versus Other Corticosteroids Used for Treatment of Mild Asthma in Children (4 to 11 Years) (BY9010/CA-101) (POPCICLE)

Asthma

Canada, Hungary, South Africa
AstraZeneca

Completed

Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490)

Rhinitis, Allergic, Perennial

United States
University of Nottingham
Nottingham University Hospitals NHS Trust; University Hospitals, Leicester

Completed

Small Particle Steroids in Refractory Asthma (SPIRA)

Asthma

United Kingdom
Sunovion

Completed

Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis

Perennial Allergic Rhinitis

United States
Sunovion

Completed

A Phase 1 Scintigraphy Study to Assess Nasal Deposition of Ciclesonide. Using a Novel Nasal Metered Dose Inhaler

Allergic Rhinitis (AR)

United Kingdom
Boehringer Ingelheim

Completed

Efficacy and Safety Comparison of Steroid or Placebo in Combination With Salmeterol and Tiotropium in COPD

Pulmonary Disease, Chronic Obstructive

Belgium, Denmark, Germany, Netherlands
AstraZeneca

Completed

Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Beclomethasone Dipropionate (HFA-BDP) in Patients With Perennial Allergic Rhinitis (PAR) (BY9010/M1-408)

Rhinitis, Allergic, Perennial

United States
Cantonal Hosptal, Baselland

Completed

The Mannitol-Asthma-Ciclesonide-Study (MACS)

Asthma, Bronchial
AstraZeneca

Completed

ATEM (Alvesco Non-interventional Study) (ATEM)

Asthma | Allergy

Austria
AstraZeneca

Completed

Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404)

Allergic Rhinitis | Perennial Allergic Rhinitis | Hay Fever

United States
Covis Pharma S.à.r.l.

Completed

Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)

Allergic Rhinitis

United States
AstraZeneca

Completed

Efficacy of Ciclesonide on Small Airways in Patients With Stable Asthma (18 to 60 y) (BY9010/M1-131)

Asthma

Netherlands
AstraZeneca

Completed

Efficacy of Ciclesonide During the Cold Season in Patients Older Than 12 Years With Persistent Asthma (ARTIST)

Asthma

Germany
AstraZeneca

Completed

Efficacy and Safety of Ciclesonide Administered With or Without Different Spacers in Patients With Asthma (12 to 75 y) (BY9010/M1-145)

Asthma

Germany, Hungary, India, Italy, Canada, France
AstraZeneca

Completed

Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)

Perennial Allergic Rhinitis | Hay Fever

United States

3

Subscribe